Drugs in this area are judged successful if they prevent deterioration. On that measure the results albeit from a small sample are impressive
"Overall, a majority of patients (16/19 evaluable at week 12) maintained or gained vision by week 12 compared to baseline and the other 3 patients that all received combination OPT-302 + Lucentis® therapy did not lose more than 3 letters (range -2 to -3 letters). The mean gain in visual acuity overall from baseline at week 12 in treatment naïve patients who received OPT-302 + Lucentis® was 16.5 letters (n=4) and 9.5 letters in the 2 mg OPT-302 + Lucentis® dose cohort (n=2). The mean visual acuity gain from baseline at week 12 in patients who showed a sub-optimal response to prior anti-VEGF-A therapy was 4 letters with combination OPT-302 + Lucentis® (n=10 evaluable patients; mean number of prior treatment injections = 10.5, range 3 – 55)."
So what`s it worth?? OPT 302 from these results improves patients treated for VEGF A alone and I`m sure Lucentis and Opthotech will have taken note.
- Forums
- ASX - By Stock
- Ann: Opthea reports positive data from Phase 1 wet AMD Trial-OPT.AX
Drugs in this area are judged successful if they prevent...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
(20min delay)
|
|||||
Last
78.0¢ |
Change
-0.010(1.27%) |
Mkt cap ! $960.2M |
Open | High | Low | Value | Volume |
79.0¢ | 79.5¢ | 74.5¢ | $2.420M | 3.109M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 77.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
78.0¢ | 77447 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 0.770 |
1 | 900 | 0.765 |
3 | 56490 | 0.750 |
2 | 5791 | 0.745 |
3 | 10831 | 0.740 |
Price($) | Vol. | No. |
---|---|---|
0.795 | 3768 | 1 |
0.800 | 94863 | 4 |
0.810 | 50000 | 1 |
0.820 | 8300 | 3 |
0.825 | 2500 | 1 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |